Archives: Agenda

How a Scaled Local Ecosystem Fuels Global Innovation 本土规模化生态如何赋能全球创新

China’s CRO/CDMO ecosystem has evolved from a basic service provider into a strategic, technologically advanced partner, offering unparalleled speed and integrated expertise. This ecosystem now serves as a fundamental and competitive pillar of the global biopharma supply chain, accelerating development and de-risking innovation for both domestic and international partners.

  • The Evolution from Cost Center to Strategic Innovation Partner
  • The Power of a Unified Service Chain
  • Specialization in New Modalities: Leading in ADC, CGT, and Beyond
  • How to Meet Global Standards
  • From Local Enabler to International Competitor

中国的CRO/CDMO生态已从基础服务商，跃升为具备战略价值的技术驱动型伙伴，以前所未有的速度与一体化专业能力，成为全球生物医药供应链中不可或缺的竞争基石，为国内外合作伙伴加速研发、降低创新风险。

  • 从成本中心到战略创新伙伴的进化之路
  • 一体化服务链的协同势能
  • 新疗法领域的专精：ADC、CGT 的领跑优势
  • 如何与国际标准全面接轨
  • 从本土赋能者到全球竞技者

KEYNOTE PANEL: The Patient Enrollment Revolution: Global Lessons from China’s Clinical Trial Efficiency 主旨圆桌：患者入组革命——中国临床试验效率的全球启示

Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution.

  • How China Building Beyond “Population Advantage”
  • How to Leverage AI and Digital Platforms in Patient Matching
  • The Power of Hospital Alliances and Regional Clinical Hubs
  • What are the most effective patient-centric strategies to ensure trial success?
  •  How to Adapt China’s Model for International Multi-Center Trials
患者入组仍然是全球药物研发中最关键的瓶颈之一，常常导致周期延误、成本攀升，并限制患者对创新疗法的可及性。在这一背景下，中国不仅凭借庞大的患者基数脱颖而出，更成为临床试验执行层面系统性创新的试验田。

  • 中国如何超越“人口红利”构建系统性优势
  • 如何利用人工智能与数字平台实现患者精准匹配
  • 医院联盟与区域临床中心的核心驱动力
  • 确保试验成功的患者中心策略有哪些有效实践
  • 如何将中国模式适配应用于国际多中心试验